In this retrospective study, 63 patients 460 years with hematological malignancies and treated with allo-SCT and with reduced-intensity conditioning (RIC) were reviewed. A total of 51% of patients suffered from AML or myelodysplastic syndromes. Disease status before transplantation was CR or PR 71 with 29% transplanted with active disease. Patients were classified according to three published prognostic indexes: (1) hematopoietic cell transplantation comorbidity index (HCT-CI); (2) European BMT (EBMT) score; and (3) Pretransplantation Assessment of Mortality (PAM) score. The 100-day and 1-year treatment-related mortality (TRM) were 6 and 22%, respectively, for the entire group. The 2-year OS and PFS were 60 and 58%, respectively. The incidence of grade II-IV acute GVHD (aGVHD) and extensive chronic GVHD was 46 and 48%, respectively. In a univariate analysis, neither the HCT-CI nor the EBMT score, nor the PAM score were predictive of TRM and OS. Only the occurrence of aGVHD affected the TRM and OS. ALLO-RIC is feasible in elderly patients. Even if those prognostic scores were not adapted to elderly patients, they did not predict for TRM and OS. aGVHD is the main cause of TRM and more efforts should be made to reduce its incidence without sacrificing graft vs tumor effect.
Introduction
Allo-SCT is the only curative therapy for many hematological malignancies. For a long period of time, this procedure was reserved for young and fit patients because of expected high regimen-related toxicity mainly due to the intensive conditioning regimens. However, for a large number of hematological diseases, the median age at diagnosis is around or after the sixth decade of life, and thus these patients originally could not benefit from allo-SCT with a myeloablative conditioning regimen (ALLO-MAC). With the introduction of reduced-intensity conditioning regimens (ALLO-RIC), this limitation has dramatically changed. By reducing the cytotoxicity related to myeloablative chemotherapy and/or TBI in conditioning regimens, toxicity has been lowered allowing treating patients excluded from transplant programs.
Several reports in the literature have demonstrated the feasibility of ALLO-RIC, using related or unrelated donors, for elderly patients with AML and myelodysplastic syndromes (MDS). 1 Recently, McClune et al. 2 presented results of 565 and 551 patients with AML or MDS, undergoing ALLO-RIC having been reported to the Center for International Blood and Marrow Transplant Research. In a multivariate analysis, age was not found to be associated with treatment-related mortality (TRM), OS and leukemia-free survival.
Despite this, only a limited number of published reports include patients 460 years; [3] [4] [5] [6] in all of these studies, except two, 4, 7 patients were transplanted for AML or MDS. Comorbidities have consistently been reported to have a great impact on the prognosis of cancer patients and different scoring systems such as the Charlson Comorbidity Index 8 have been reported, and are widely used in medical oncology. However, none of these were adapted to patients undergoing allo-SCT. Recently, Sorror et al. 9 developed a specific comorbidity score adapted to allo-SCT patients, having Charlson Comorbidity Index as the backbone. This hematopoietic cell transplantation comorbidity index (HCT-CI) is composed of 17 variables and has been validated in a cohort of 41000 patients treated with allo-SCT. It segregated three groups of patients with significantly different TRM and OS. 9 HCT-CI, eventually coupled with performance status, 10 was reported to have a higher prognostic impact than age, suggesting that HCT-CI can guide physician's choice to a more riskadapted strategy. Furthermore, the validity of HCT-CI score has been verified in retrospective studies of only ALLO-RIC patients. [10] [11] [12] At least two other scoring systems (Pretransplantation Assessment of Mortality (PAM) score and European BMT (EBMT) score) have been published, both capturing patient and disease characteristics, donor type and age, identifying groups with different survival and/or TRM. 13, 14 However, for one of them only patients with myeloid malignancies were included. 13 The aim of this retrospective single-center study was to analyze OS and TRM in a cohort of patients 460 years of age with different hematological malignancies and undergoing ALLO-RIC. In addition, we analyzed for the validity of these three different prognostic scoring systems: HCT-CI, PAM and the EBMT systems.
Patients and methods
From 2001 to 2008, 278 consecutive patients received an ALLO-RIC in the Institut Paoli Calmettes. Of these patients, 63 (23%) were 460 years of age and were selected for this study.
Patients and inclusion criteria At our institution, age was not an independent contraindication for undergoing ALLO-RIC. In this cohort, patients were affected by different hematological malignancies for which a clear indication to allograft was established. This study was approved by the local ethics committee.
Conditioning regimens and GVHD prophylaxis
Three RICs were used during the study time. One consisted of fludarabine (30 mg/m 2 /day for 5 days), oral or i.v. BU (4 mg/kg/day or 3.2 mg/kg/day, respectively, over 2 days) and thymoglobulin (2.5 mg/kg/day over 1 or 2 days). For these patients, GVHD prophylaxis was CYA alone starting from days À3 at 3 mg/kg/day, then adjusted on the basis of dose levels. Second conditioning consisted of fludarabine (30 mg/m 2 /day for 3 days) and low-dose TBI (2 gray). For these patients, GVHD prophylaxis consisted of CYA and mycophenolate mofetil (MMF) for 28 or 56 days after transplant depending on donor type (identical sibling vs unrelated donor). Conditioning was chosen according to disease status and the eligibility for ongoing trials. Alternatively, patients receiving cord blood were all conditioned with CY (50 mg/kg), fludarabine (40 mg/m 2 /day for 5 days) and TBI (2 Gy); CYA and MMF were used for GVHD prophylaxis.
Acute (aGVHD) and chronic GVHD (cGVHD) diagnosis, grading and treatment were done according to international guidelines, as previously reported. 15 Chimerism analysis was evaluated by PCR variable number tandem repeat heterogeneity on CD3 selected lymphocytes at fixed time point as previously reported. 15 CYA dose management was adjusted on the basis of chimerism results and disease status. In case of mixed chimerism (defined as 45% of recipient cells) and for, progressing or relapsing patients, whatever chimerism status was found, donor lymphocytes infusions could be performed, starting with 1 Â 10 7 CD3 þ cells/kg of recipient, after CYA withdrawal.
Supportive care
All patients were admitted in a single room, each equipped with high-efficiency particulate air filtration system.
Antifungal and antibacterial prophylaxis changed during the study period, but all patients received antifungal prophylaxis (either fluconazole, voriconazole or caspofungin), whereas more recently, antibacterial prophylaxis was abandoned.
RBC transfusion was performed for a hemoglobin level o8 g/l, and single-donor platelet transfusion for a platelet count that was o10 Â 10 9 /l or when medically indicated.
Study definitions and statistical methods
Descriptive analysis of data was performed according to standard methodology. OS was defined as the probability of survival irrespective of disease state at any point of time after transplantation. Patients alive were censored at their last follow-up.
PFS was defined as the probability of being alive free of disease at any point of time after transplantation. Thus, death or disease relapse/progression was treated as events. Patients alive and free of disease were censored at their last follow-up. OS and PFS were estimated by the KaplanMeier method, 16 and compared using log-rank test. Hazard ratios were estimated using a Cox proportional regression model. TRM incidence was defined as the hazards probability of dying from a cause not related to the underlying malignancy evolution. TRM was estimated by the Prentice method, and compared by the Gray test. For OS, PFS and TRM end points, time-dependant Cox model analysis was used to estimate hazard ratios for timedependant covariables (aGVHD, cGVHD). Data needed for elaborating each of the three scores were collected. The search for factors potentially influencing TRM and OS was initiated in a univariate analysis. Statistical analysis was performed using R.2.11.1 software (R Development Core Team, http://www.R-project.org)
Results
Data from the 63 patient charts were retrospectively reviewed and extracted. Main patient characteristics are shown in Table 1 . The median age was 63 (range 60-70) years. Half of the patients were between 60 and 65 years and half between 65 and 70 years. A total of 47% of patients had AML (Table 1) . Patients were retrospectively classified according to the three prognostic scoring systems (Table 2) . Regarding HCT-CI, the distribution was quite homogenous across the three groups, whereas most patients were in the intermediate groups according to the PAM score and EBMT score classification. In all, 27% of the patients had a performance status p80%. The median follow-up for surviving patients was 22 (range 8-82) months.
GVHD
The incidence of grade II-IV aGVHD incidence was 46% (n ¼ 29) and the grade III-IV aGVHD incidence was 22% (n ¼ 14). The median time from transplantation for the aGVHD diagnosis was 41 days (range 13-177). In all. 58% of the patients (92%) were evaluable for cGVHD. The overall incidence of cGVHD was 48% (n ¼ 28), and 78% were graded as extensive. The median time between allogeneic and extensive cGVHD diagnosis was 157 (range 98-359) days. The incidence of II-IV aGVHD and extensive cGVHD was higher with unrelated donors as compared with HLA identical siblings (72 vs 43% and 50 vs 30%). These differences were not statistically significant (P ¼ 0.1).
Toxicities and TRM
All but one patient engrafted. This patient was transplanted for primary myelofibrosis and disease progression was diagnosed at time of failure. Six patients (10%) did not fall below an ANC of o0.5 Â 10 9 /l. Other patients achieved stable ANC (40.5 Â 10 9 /l) at a median time of 18 days (8-79). Platelet count was not below 20 Â 10 9 /l in 26 patients (39%). For the other patients, the median time to achieve a stable platelet count (420 Â 10 9 /l untransfused) was 12 (range 3-134) days.
Infectious complications were analyzed as occurring prior (early) or after (late) 100 days after transplantation. In the early period, fever of unknown origin (FUO) was documented in 41% of patients (n ¼ 26) and documented infections in 36% (n ¼ 23). FUO was not observed in the late period, whereas documented infections were found in 11% (n ¼ 11/58). No patient died from early infections, whereas nine patients (50%) died from infections in the late period (two encephalitis, two septic shock and five pneumonia). Ten pairs were both negative for CMV, and none of these developed infections. In the remaining patients (n ¼ 53), CMV reactivation was observed in 32% (n ¼ 17), with only one patient developing CMV colitis.
Early extrahematological toxicity was generally mild. Eight patients (12%) showed liver toxicity but only severely (grade III-IV) so in two of them. Renal toxicity was more frequent (n ¼ 12, 18%), but none developed severe renal impairment. Mild heart toxicity was observed in three patients (4%) and neurological toxicity in one patient. The 100-day and 1-year TRM were 6 and 22%, respectively (Figure 1 ).
Survival
For all patients, the 2-year OS and PFS were 60 and 58%, respectively (Figures 2 and 3) . 
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Prognostic factors for TRM and OS None of the investigated pretransplant factors were found to have an influence on TRM or OS (Table 3) . Inversely, development of grade II-IV aGVHD dramatically increased TRM and decreased OS. cGVHD did not impact on TRM and OS. Because of this observation, no multivariate analysis was performed.
Discussion
This study confirmed that ALLO-RIC can be well tolerated by patients 460 years with various hematological malignancies. Several studies of ALLO-RIC for patients with AML or MDS have been published. Bertz et al. 5 analyzed the outcome of 19 AML patients (median age 64 years) with active disease at time of transplantation. After RIC (fludarabine, intermediate-dose melphalan and BCNU), matched unrelated donor or HLA identical sibling peripheral stem cells were infused. The grade II-IV aGVHD incidence was 59%, with no difference between matched unrelated donor and sibling donor. Extensive cGVHD was observed in 41%. The 1-year non-relapse mortality and OS probability estimates were 22 and 68%, respectively. Allo-SCT in elderly patients L Castagna et al
Spyridonidis et al. 6 extended previous results 5 on 34 patients (median age 63 years) receiving the same RIC regimen and matched unrelated donor. GVHD prophylaxis consisted of CYA, MMF and antithymocyte globulin Fresenius. Overall, at 2 years, TRM and relapse cumulative incidences were 19.6 and 27%, respectively. Grade II-IV aGVHD incidence was 42 and only 13% of patients developed extensive cGVHD. The 2-year OS and EFS were 60 and 53%, respectively. Gupta et al.
3 treated 24 patients (median age 64 years) with MDS and AML with ALLO-RIC (fludarabine plus TBI (FTBI), GVHD prophylaxis CYA plus MMF) using HLA-identical siblings. The 2-year OS and PFS probabilities were 52 and 44%, respectively. In addition, 100-day and 1-year TRM cumulative incidences were 8 and 17%, respectively. Also, grade II-IV aGVHD and cGVHD incidences were 45 and 74%, respectively.
Only two studies concerning elderly patients treated with ALLO-RIC referred to patients diagnosed with more heterogeneous diagnoses. Shapira et al.
7 treated 17 elderly patients (median age 62 years) with advanced hematological malignancies. They were conditioned with different combination of fludarabine and BU before an HLA-identical sibling, HLA-non-identical sibling or matched unrelated donor transplantation. In this study, as expected, the TRM was quite high (33%), but one-third of the patients survived and remained in CR after 1 year. Falda et al. 4 conducted a prospective trial in similar patients (n ¼ 36), conditioned by FTBI (GVHD prophylaxis CYA plus MMF). Results were encouraging if patients were in CR at the time of transplant. The 1-year TRM was 10%; aGVHD and cGVHD incidence were 48 and 83%, respectively.
Our results are in line with these data in terms of TRM (22% at 2 years), 2-year OS and PFS (60 and 58%, respectively). However, we believe that the diagnostic heterogeneity of our population makes our data more applicable for a mixed patient population. Our study is limited by its retrospective nature, carrying the inherent risks of patient selection bias. Indeed, we analyzed only patients effectively receiving ALLO-RIC and then we can thus not conclude on its general applicability. It is known that only 5% of elderly patients with AML are usually allografted. 17 However, age alone can no longer be considered a contraindication for allo-SCT when elderly patients have an indication for this procedure. We recognize that the heterogeneity of the conditioning regimens used with or without in vivo T-cell depletion by antithymocyte globulin and GVHD prophylaxis in our study may limit its applicability. However, in the univariate analysis, antithymocyte globulin-containing RIC was not associated with a different outcome. Furthermore, even if most of the patients were allografted with an HLAidentical sibling, almost 30% received an adult alternative donor or cord blood. Although aGVHD incidence was higher with alternative donors, the TRM was not statistically different.
In addition, the originality of this study lies on the fact that three recently published prognostic scores 9, 13, 14 were also tested for TRM and OS. The HCT-CI is an adaptation of Charlson Comorbidity Index to allografted patients. This score defined three groups (0, 1-2, X3) statistically influencing TRM and OS. 10 However, recipient age was not considered, whereas performance status assumed a relevant importance when only ALLO-RIC was considered for analysis. 9 In addition, this score was established and validated in a heterogeneous population incorporating young and older patients, myeloablative regimen and RIC, BM and PBSC transplant, related and unrelated transplants, raising the question of its validity in more homogenous populations. Indeed, several studies already addressed this concern. The validity of HCT-CI has been confirmed recently in lymphoma and myeloma patients treated with ALLO-RIC, 11 but other studies did not reproduce these results. 18, 19 The patient population was equally distributed across the three different subgroups witnessing that this population was not positively selected. However, neither TRM nor OS were different within the three groups (Table 3) .
Patients were also analyzed using two other scoring systems, 13, 14 which have not been previously validated for ALLO-RIC, and incorporating age as a definite prognostic categorical variable, contrary to the first one. PAM score 13 considers eight variables, including age, donor type, disease stage, conditioning regimens and indicators of organ function. In our study, most patients were included in the intermediate categories (score 17-23 and 24-30). We found that TRM and OS did not differ according to this score ( Table 3) .
The EBMT score, 14 initially applied to chronic myeloid leukemia, has subsequently been investigated and validated for several malignancies, and includes age and variables directly related to transplantation. Obviously, our patients had at least a score 2 (linked to age). Again, no differences in terms of TRM and OS were found (Table 3) .
In univariate analysis, only aGVHD occurrence was associated with a high risk of TRM (P ¼ 0.00319), whereas extensive cGVHD was not. Furthermore, in this analysis it was shown that donor source, disease type and age (o65 vs 465) did not influence TRM. Altogether, these results, despite the obvious biases of this retrospective study, shows that we should be cautious using any of the studied scores when making transplant decisions for the elderly. However, it should be pointed out that the patient population is too small to conclude on this field and that probably an ad hoc study dealing with elderly patients should be performed to obtain an appropriate prognostic score.
We conclude that ALLO-RIC should be routinely included in the discussion of treatment strategy of elderly patients with hematological malignancies. However, better tools predicting TRM and OS are still needed.
